STAT1 and colorectal carcinoma: Interestingly, recent developments of therapeutic approaches are considering the pharmacological blockage of STAT3 signaling43, however, given our findings of already reduced STAT1 and 3 in CRC tumors and also the association of low STAT1 concomitant with STAT3 with reduced survival of CRC patients41, great caution should be taken when designing such therapies.